VALN
HealthcareValneva SE · Biotechnology · $530M
What is Valneva SE?
Valneva SE is a French specialty vaccine company focused on developing and commercializing prophylactic vaccines for infectious diseases where treatment options remain limited. The company targets niche travel health and emerging infectious disease markets.
Valneva generates revenue primarily through two commercial travel vaccines — one targeting Japanese encephalitis and another addressing cholera and traveler's diarrhea. Beyond its marketed products, the company advances a pipeline of vaccine candidates, including programs targeting Lyme disease (in collaboration with Pfizer) and chikungunya virus. Revenue depends on travel health demand and the successful advancement of late-stage clinical programs toward regulatory approval and eventual commercialization.
Valneva was founded in 1998 and is headquartered in Saint-Herblain, France.
- IXIARO — inactivated Japanese encephalitis vaccine for travelers
- DUKORAL — oral vaccine against cholera and traveler's diarrhea
- VLA15 — Lyme disease vaccine candidate, co-developed with Pfizer
- VLA1553 — chikungunya vaccine candidate in Phase III trials
- Collaboration with Instituto Butantan for chikungunya vaccine development
Is VALN a Good Stock to Buy?
UQS Score rates VALN as Below Average overall, reflecting meaningful challenges across several fundamental dimensions.
The most constructive elements of Valneva's profile sit in its Valuation and Growth pillars. The Valuation pillar is rated Attractive, suggesting the market may already be pricing in significant uncertainty — which can create a different risk-reward dynamic for investors with a high risk tolerance. The Growth pillar registers as Neutral, reflecting a pipeline with potential but no near-term certainty.
Both the Quality and Moat pillars are rated Weak, pointing to limited competitive durability and financial fragility relative to peers in the healthcare sector. The Risk pillar is Neutral, but clinical-stage dependence amplifies downside scenarios.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does VALN pay dividends?
No — Valneva SE does not currently pay a dividend.
Valneva does not currently pay a dividend. For a clinical-stage-heavy specialty vaccine company, this is typical — available capital is directed toward research, clinical trials, and regulatory activities rather than shareholder distributions. Investors in VALN are generally seeking pipeline-driven capital appreciation rather than income.
When does VALN report earnings?
Valneva reports earnings on a regular cadence consistent with its listing obligations as a publicly traded company.
Revenue trends are closely tied to travel health demand for its commercial vaccines and milestone payments from partnerships. Pipeline progress — particularly in Lyme disease and chikungunya — tends to drive market reaction more than near-term revenue figures.
For the most recent quarter's results, visit Valneva's official investor relations page.
VALN Price History
-77.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Valneva SE?
Based on Valneva SE's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
VALN Long-term Outlook
Valneva's fundamental outlook is shaped by the interplay between its Neutral Growth profile and the Weak Quality and Moat ratings. The pipeline holds genuine optionality — particularly the Lyme disease program partnered with Pfizer — but converting that optionality into durable revenue growth remains the central challenge. The Attractive Valuation label suggests limited near-term upside expectations are already embedded in the price, which could work in favor of long-term holders if pipeline milestones are met.
Growth drivers
- Advancement of the Lyme disease vaccine candidate through regulatory review with Pfizer
- Potential chikungunya vaccine approval and commercialization via VLA1553
- Recovery and expansion of travel health vaccine demand post-pandemic
Key risks
- Clinical trial failure or regulatory setbacks in late-stage pipeline programs
- Dependence on a narrow commercial product base for near-term revenue
- Execution risk in scaling manufacturing and commercial infrastructure
VALN vs Peers
Valneva operates in a niche corner of the healthcare sector, and its peer group reflects the diversity of small-cap biotech and specialty therapeutics companies.
Contineum focuses on small-molecule therapeutics for neurological and inflammatory conditions, representing a different therapeutic modality than Valneva's vaccine-centric approach.
MiMedx specializes in regenerative medicine and tissue products, operating in wound care rather than infectious disease prevention.
DBV Technologies is a French biotech developing epicutaneous immunotherapy for food allergies, sharing Valneva's European roots but targeting a distinct immunology market.
Frequently Asked Questions
What does Valneva do?
Valneva SE is a specialty vaccine company that develops and sells prophylactic vaccines for infectious diseases with limited existing solutions. Its commercial portfolio covers travel health indications, while its pipeline targets diseases like Lyme disease and chikungunya. The company operates internationally and has key partnerships with Pfizer and Instituto Butantan.
Does VALN pay dividends?
Valneva does not pay a dividend. The company reinvests available resources into its clinical pipeline and commercial operations. Investors in VALN are typically focused on pipeline-driven value creation rather than income generation.
When does VALN report earnings?
Valneva reports financial results on a regular periodic cadence in line with its listing requirements. For exact upcoming report dates, check Valneva's investor relations page directly, as our data source does not cover specific future earnings dates.
Is VALN a good stock to buy?
UQS Score rates VALN as Below Average, driven by Weak Quality and Moat pillar ratings. The Valuation pillar is Attractive, which may interest contrarian investors, but the overall profile reflects meaningful fundamental risk. Reviewing the full pillar breakdown on UQS Pro can help inform your own assessment.
Is VALN overvalued?
Based on the UQS Valuation pillar, VALN is rated Attractive — meaning the current price appears to reflect limited optimism relative to the company's fundamentals. This does not eliminate risk, particularly given the Weak Quality and Moat ratings, but it suggests the market has already discounted significant uncertainty.
How does VALN compare to its competitors?
Valneva's peer group in the small-cap healthcare space includes companies with different therapeutic focuses — from regenerative medicine to immunotherapy. Valneva's distinguishing characteristic is its vaccine-specific focus and its partnership with a major pharmaceutical company on Lyme disease. Full UQS Score comparisons are available to Pro members.
What is VALN's market cap bracket?
Valneva SE is classified as a small-cap company. This places it in a segment of the market characterized by higher volatility, greater sensitivity to clinical trial outcomes, and typically lower liquidity compared to large- or mega-cap healthcare peers.
Who founded Valneva?
Valneva SE was formed through the merger of Intercell AG and Vivalis in 2013, though the company traces its origins to 1998. Founding and corporate history details are publicly available through Valneva's official communications and investor relations materials.
Is VALN a long-term quality indicator stock?
As a long-term quality indicator, VALN's profile is mixed. The Weak Quality and Moat pillars suggest the business lacks the durable competitive advantages and financial consistency typically associated with long-term compounders. The pipeline optionality — particularly in Lyme disease — could change this profile if key programs succeed, but that outcome remains uncertain.
What is the main competitive advantage of Valneva?
Valneva's primary differentiator is its specialized expertise in developing vaccines for niche infectious diseases that larger pharmaceutical companies have historically underserved. Its partnership with Pfizer on the Lyme disease program provides both validation and commercial infrastructure that a small-cap company would struggle to build independently.
What sector does VALN belong to?
Valneva SE operates in the Healthcare sector, specifically within the specialty vaccines and biopharmaceuticals segment. Its focus on prophylactic vaccines for travel health and emerging infectious diseases places it in a niche corner of the broader healthcare landscape.
Is VALN a growth stock or value stock?
VALN sits in an unusual position: its Growth pillar is rated Neutral, reflecting pipeline potential without near-term revenue certainty, while its Valuation pillar is Attractive. This combination may appeal to investors seeking undervalued pipeline exposure, though the Weak Quality rating tempers a straightforward growth or value classification.
Unlock Full VALN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access full financial metrics and trend data
- ✓Compare VALN against sector peers side by side
- ✓Track pipeline risk indicators within the Risk pillar
- ✓Get the complete analyst-grade view for Pro members
- ✓Screen for Attractive-valuation healthcare stocks like VALN
Pro Analysis
VALN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 6, 2026 | 40.9 | 7.1 | 23.0 | 51.9 | 53.7 | 100.0 | +23.9 |
| Apr 5, 2026 | 17.0 | 7.1 | 23.0 | 6.9 | 53.7 | 0.0 | -23.9 |
| Apr 2, 2026 | 40.9 | 7.1 | 23.0 | 51.9 | 53.7 | 100.0 | — |
VALN — Pillar Breakdown
Quality
— 7.1/100 (25%)Valneva SE currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 51.9/100 (20%)Valneva SE shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 50.7/100 (15%)Valneva SE has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 100.0/100 (15%)Valneva SE appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 23/100 (25%)Valneva SE operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for VALN.
Score Composition
Financial Data
More Stock Analysis
How is the VALN UQS Score Calculated?
The UQS (Unified Quality Score) for Valneva SE is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Valneva SE's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Valneva SE is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.